Cargando…

Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation

Due to its ability to compensate for signals lost following therapeutic MAPK-inhibition, insulin-like growth factor type 1 receptor (IGF-1R) co-targeting is a rational approach for melanoma treatment. However IGF-1R conformational changes associated with its inhibition can preferentially activate MA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suleymanova, Naida, Crudden, Caitrin, Worrall, Claire, Dricu, Anica, Girnita, Ada, Girnita, Leonard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669887/ https://www.ncbi.nlm.nih.gov/pubmed/29137261 http://dx.doi.org/10.18632/oncotarget.19286

Ejemplares similares

Targeting the IGF-1R: The Tale of the Tortoise and the Hare
por: Crudden, Caitrin, et al.
Publicado: (2015)

Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma
por: Worrall, C, et al.
Publicado: (2017)

Below the Surface: IGF-1R Therapeutic Targeting and Its Endocytic Journey
por: Crudden, Caitrin, et al.
Publicado: (2019)

Functional antagonism of β-arrestin isoforms balance IGF-1R expression and signalling with distinct cancer-related biological outcomes
por: Suleymanova, N, et al.
Publicado: (2017)

Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation
por: Girnita, Leonard, et al.
Publicado: (2013)

Role of Ubiquitination in IGF-1 Receptor Signaling and Degradation
por: Sehat, Bita, et al.
Publicado: (2007)

Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment
por: Helgadottir, Hildur, et al.
Publicado: (2018)

It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease
por: Girnita, Leonard, et al.
Publicado: (2022)

Non-Coding RNAs in IGF-1R Signaling Regulation: The Underlying Pathophysiological Link between Diabetes and Cancer
por: Chen, Baoqing, et al.
Publicado: (2019)

Differences in cutaneous melanoma treatment and patient satisfaction
por: Wikstrom, Jakob D., et al.
Publicado: (2018)

Correction: Differences in cutaneous melanoma treatment and patient satisfaction
por: Wikstrom, Jakob D., et al.
Publicado: (2021)

IRS-2 deubiquitination by USP9X maintains anchorage-independent cell growth via Erk1/2 activation in prostate carcinoma cell line
por: Furuta, Haruka, et al.
Publicado: (2018)

Ten-year Follow-up Study of Grenz Ray Treatment for Lentigo Maligna and Early Lentigo Maligna Melanoma
por: DRAKENSJÖ, Iara R. T., et al.
Publicado: (2020)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

Role of insulin-like growth factor 1 receptor signalling in cancer
por: Larsson, O, et al.
Publicado: (2005)

Editorial: DNA damage response pathways meet endocrine systems
por: Werner, Haim, et al.
Publicado: (2023)

RETRACTED ARTICLE:Identification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptor
por: Girnita, A, et al.
Publicado: (2011)

Decrypting noncoding RNA interactions, structures, and functional networks
por: Fabbri, Muller, et al.
Publicado: (2019)

Biased and unbiased perceptual decision-making on vocal emotions
por: Dricu, Mihai, et al.
Publicado: (2017)

When Should a Patient with Statin-Induced Myopathy Be Re-challenged? A Case of Necrotizing Autoimmune Myopathy
por: Obreja, Elena, et al.
Publicado: (2018)

Prediction of BAP1 Expression in Uveal Melanoma Using Densely-Connected Deep Classification Networks
por: Sun, Muyi, et al.
Publicado: (2019)

MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018)

Bullous Pemphigoid-like Eruption Triggered by Targeted Therapy for Metastatic Melanoma
por: ERIKSSON, Hanna, et al.
Publicado: (2020)

Sjogren’s Syndrome Presenting with Solely Cutaneous Features
por: Centala, Sneha, et al.
Publicado: (2021)

Oncogenic Signalling of Growth Factor Receptors in Cancer: Mechanisms and Therapeutic Opportunities
por: Dricu, Anica
Publicado: (2022)

When Chest Pain Reveals More: A Case of Hydrochlorothiazide-Induced Systemic Lupus Erythematosus
por: Sosenko, Teresa, et al.
Publicado: (2019)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

Trametinib: a MEK inhibitor for management of metastatic melanoma
por: Lugowska, Iwona, et al.
Publicado: (2015)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas
por: Wang, Qing, et al.
Publicado: (2020)

Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma
por: Smith, Michael P., et al.
Publicado: (2013)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)

Monosomy 3 Is Linked to Resistance to MEK Inhibitors in Uveal Melanoma
por: Mergener, Svenja, et al.
Publicado: (2021)

Molecular Characterization of Acquired Tolerance of Tumor Cells to Picropodophyllin (PPP)
por: Hashemi, Jamileh, et al.
Publicado: (2011)

Histone deacetylase inhibitors: a promising partner for MEK inhibitors in uveal melanoma?
por: Faião-Flores, Fernanda, et al.
Publicado: (2019)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
por: Booth, Andrew E. C., et al.
Publicado: (2020)

A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours
por: Wilky, B A, et al.
Publicado: (2015)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
por: Stones, Clare J., et al.
Publicado: (2013)

MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy
por: Tran, Khiem A, et al.
Publicado: (2015)

Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
por: Ryu, Sunhyo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hsms95ma2opcitvj2l76i62blf